{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:42:19Z","timestamp":1791567739498,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.transci.2022.103457","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T13:32:19Z","timestamp":1652275939000},"page":"103457","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utilization of emicizumab in acquired hemophilia A: A case report"],"prefix":"10.1016","volume":"61","author":[{"given":"Sean G.","family":"Yates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Sarode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim F.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Min P.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2022.103457_bib1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: Results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2022.103457_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2022.103457_bib3","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103457_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2022.103457_bib5","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.transci.2022.103457_bib6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jth.14746","article-title":"An anti-factor IXa\/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A","volume":"18","author":"Takeyama","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2022.103457_bib7","article-title":"Ex Vivo Prediction of Comprehensive Coagulation Potential Using Simulated Blood Concentrations of Emicizumab in Patients with Acquired Hemophilia A","author":"Takeyama","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.transci.2022.103457_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000497287","article-title":"Emicizumab in the Treatment of Acquired Haemophilia: A Case Report","volume":"46","author":"M\u00f6hnle","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2022.103457_bib9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.12659\/AJCR.916783","article-title":"Emicizumab use in treatment of acquired hemophilia A: A case report","volume":"20","author":"Al-Banaa","year":"2019","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.transci.2022.103457_bib10","first-page":"e585","article-title":"Emicizumab reduces re-hospitalization for bleeding in acquired","volume":"27","author":"Chen","year":"2021","journal-title":"haemophilia A. Haemophilia"},{"key":"10.1016\/j.transci.2022.103457_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2021-242876","article-title":"Acquired haemophilia A: Successful treatment of a patient using upfront immunosuppressive therapy and haemostatic agents","volume":"14","author":"Chung","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.transci.2022.103457_bib12","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/rth2.12201","article-title":"Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention","volume":"3","author":"Dane","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.transci.2022.103457_bib13","doi-asserted-by":"crossref","first-page":"e502","DOI":"10.1111\/hae.14225","article-title":"Persistent inhibitor in acquired haemophilia A: A case for emicizumab?","volume":"27","author":"Ganslmeier","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2022.103457_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211038193","article-title":"Emicizumab in acquired haemophilia A: about two clinical cases and literature review","volume":"12","author":"Hansenne","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.transci.2022.103457_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/AJCR.922326","article-title":"Utilization of emicizumab in acquired factor VIII deficiency","volume":"21","author":"Hess","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.transci.2022.103457_bib16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103457_bib17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: The story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2022.103457_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: Results from the European Acquired Haemophilia (EACH2) registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103457_bib19","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.transci.2022.103457_bib20","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00277-018-3372-z","article-title":"Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia","volume":"97","author":"Tiede","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.transci.2022.103457_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6\u2013year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2022.103457_bib22","first-page":"1091","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.transci.2022.103457_bib23","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII\u2013mimetic function of humanized bispecific antibody in hemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2022.103457_bib24","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with hemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2022.103457_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136488","article-title":"An Investigational Dosing Algorithm of Emicizumab for Prophylaxis in Acquired Hemophilia a","volume":"136","author":"Shima","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103457_bib26","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: Results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103457_bib27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired Hemophilia: A Natural History Study of 16 Patients With Factor VIII Inhibitors Receiving Little or No Therapy","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.transci.2022.103457_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/jth.15515","article-title":"Predictive significance of anti\u2010FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: Results from the Quebec Reference Center for Inhibitors","author":"Bonnefoy","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222001306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050222001306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:55:27Z","timestamp":1761468927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050222001306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1473050222001306"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2022.103457","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization of emicizumab in acquired hemophilia A: A case report","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2022.103457","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103457"}}